BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 9990072)

  • 1. Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis.
    Longley BJ; Metcalfe DD; Tharp M; Wang X; Tyrrell L; Lu SZ; Heitjan D; Ma Y
    Proc Natl Acad Sci U S A; 1999 Feb; 96(4):1609-14. PubMed ID: 9990072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of paediatric mastocytosis with a polymorphism resulting in an amino acid substitution (M541L) in the transmembrane domain of c-KIT.
    Foster R; Byrnes E; Meldrum C; Griffith R; Ross G; Upjohn E; Braue A; Scott R; Varigos G; Ferrao P; Ashman LK
    Br J Dermatol; 2008 Nov; 159(5):1160-9. PubMed ID: 18795925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of activating c-kit mutations in adult-, but not in childhood-onset indolent mastocytosis: a possible explanation for divergent clinical behavior.
    Büttner C; Henz BM; Welker P; Sepp NT; Grabbe J
    J Invest Dermatol; 1998 Dec; 111(6):1227-31. PubMed ID: 9856847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of lesional skin c-KIT mutations with clinical phenotype in patients with mastocytosis.
    Chan IJ; Tharp MD
    Clin Exp Dermatol; 2018 Jun; 43(4):416-422. PubMed ID: 29350409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Therapeutically relevant mutations in the receptor tyrosine kinase KIT in mastocytosis].
    Sotlar K
    Verh Dtsch Ges Pathol; 2007; 91():169-76. PubMed ID: 18314612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pediatric mastocytosis.
    Hartmann K; Metcalfe DD
    Hematol Oncol Clin North Am; 2000 Jun; 14(3):625-40. PubMed ID: 10909043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations.
    Bodemer C; Hermine O; Palmérini F; Yang Y; Grandpeix-Guyodo C; Leventhal PS; Hadj-Rabia S; Nasca L; Georgin-Lavialle S; Cohen-Akenine A; Launay JM; Barete S; Feger F; Arock M; Catteau B; Sans B; Stalder JF; Skowron F; Thomas L; Lorette G; Plantin P; Bordigoni P; Lortholary O; de Prost Y; Moussy A; Sobol H; Dubreuil P
    J Invest Dermatol; 2010 Mar; 130(3):804-15. PubMed ID: 19865100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel germline mutation of KIT associated with familial gastrointestinal stromal tumors and mastocytosis.
    Hartmann K; Wardelmann E; Ma Y; Merkelbach-Bruse S; Preussner LM; Woolery C; Baldus SE; Heinicke T; Thiele J; Buettner R; Longley BJ
    Gastroenterology; 2005 Sep; 129(3):1042-6. PubMed ID: 16143141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder.
    Nagata H; Worobec AS; Oh CK; Chowdhury BA; Tannenbaum S; Suzuki Y; Metcalfe DD
    Proc Natl Acad Sci U S A; 1995 Nov; 92(23):10560-4. PubMed ID: 7479840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutation analysis of C-KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis.
    Fritsche-Polanz R; Jordan JH; Feix A; Sperr WR; Sunder-Plassmann G; Valent P; Födinger M
    Br J Haematol; 2001 May; 113(2):357-64. PubMed ID: 11380399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. C-kit mutations and mast cell disorders. A model of activating mutations of growth factor receptors.
    Pignon JM
    Hematol Cell Ther; 1997 Apr; 39(2):114-6. PubMed ID: 9168310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances in mastocytosis research. Summary of the Vienna Mastocytosis Meeting 1998.
    Valent P; Escribano L; Parwaresch RM; Schemmel V; Schwartz LB; Sotlar K; Sperr WR; Horny HP
    Int Arch Allergy Immunol; 1999 Sep; 120(1):1-7. PubMed ID: 10529583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The novel KIT exon 11 germline mutation K558N is associated with gastrointestinal stromal tumor, mastocytosis, and seminoma development.
    Meir M; Maurus K; Kuper J; Hankir M; Wardelmann E; Rosenwald A; Germer CT; Wiegering A
    Genes Chromosomes Cancer; 2021 Dec; 60(12):827-832. PubMed ID: 34338390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations.
    Ma Y; Zeng S; Metcalfe DD; Akin C; Dimitrijevic S; Butterfield JH; McMahon G; Longley BJ
    Blood; 2002 Mar; 99(5):1741-4. PubMed ID: 11861291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pediatric mastocytosis-associated KIT extracellular domain mutations exhibit different functional and signaling properties compared with KIT-phosphotransferase domain mutations.
    Yang Y; Létard S; Borge L; Chaix A; Hanssens K; Lopez S; Vita M; Finetti P; Birnbaum D; Bertucci F; Gomez S; de Sepulveda P; Dubreuil P
    Blood; 2010 Aug; 116(7):1114-23. PubMed ID: 20484085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances in the understanding of mastocytosis: the role of KIT mutations.
    Orfao A; Garcia-Montero AC; Sanchez L; Escribano L;
    Br J Haematol; 2007 Jul; 138(1):12-30. PubMed ID: 17555444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mastocytosis in mice expressing human Kit receptor with the activating Asp816Val mutation.
    Zappulla JP; Dubreuil P; Desbois S; Létard S; Hamouda NB; Daëron M; Delsol G; Arock M; Liblau RS
    J Exp Med; 2005 Dec; 202(12):1635-41. PubMed ID: 16352739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm.
    Longley BJ; Tyrrell L; Lu SZ; Ma YS; Langley K; Ding TG; Duffy T; Jacobs P; Tang LH; Modlin I
    Nat Genet; 1996 Mar; 12(3):312-4. PubMed ID: 8589724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit.
    Akin C; Brockow K; D'Ambrosio C; Kirshenbaum AS; Ma Y; Longley BJ; Metcalfe DD
    Exp Hematol; 2003 Aug; 31(8):686-92. PubMed ID: 12901973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. c-Kit and c-kit mutations in mastocytosis and other hematological diseases.
    Boissan M; Feger F; Guillosson JJ; Arock M
    J Leukoc Biol; 2000 Feb; 67(2):135-48. PubMed ID: 10670573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.